Table 4. Comparison between changes of ESR1 and PIK3CA mutations and each therapeutic drug in 52 MBC patients with longitudinal data.
| Genomic state | No. of patients (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Representative treatment between blood draws | |||||||||
| Total | No | AI | SERM | SERD | EE2 | MPA | Chemotherapy | ||
| (N = 52) | (N = 7) | (N = 15) | (N = 5) | (N = 8) | (N = 5) | (N = 2) | (N = 10) | ||
| ESR1 | WT | 28 (53.8) | 7 (100) | 9 (60) | 1 (20) | 1 (12.5) | 2 (40) | 1 (50) | 7 (70) |
| Acquires or maintenance of mutation numbers | 15 (28.8) | 0 | 4 (26.7) | 2 (40) | 5 (62.5) | 1 (20) | 1 (50) | 2 (20) | |
| Disappears in mutation numbers | 9 (17.3) | 0 | 2 (13.3) | 2 (40) | 2 (25) | 2 (40) | 0 | 1 (10) | |
| PIK3CA | WT | 31 (59.6) | 7 (100) | 10 (75) | 3 (60) | 5 (62.5) | 2 (40) | 1 (50) | 3 (30) |
| Acquires or maintenance of mutation numbers | 18 (34.6) | 0 | 5 (25) | 1 (20) | 3 (37.5) | 3 (60) | 1 (50) | 5 (50) | |
| Disappears in mutation numbers | 3 (5.8) | 0 | 0 | 1 (20) | 0 | 0 | 0 | 2 (20) | |
Abbreviations: WT, wild-type; AI, aromatase inhibitor; SERM, selective estrogen receptor modulator; SERD, selective estrogen receptor downregulator; EE2, Ethinyl estradiol; MPA, medroxyprogesterone acetate.